CN117915945A - 用于covid-19疫苗的新型蛋白质和核酸序列 - Google Patents

用于covid-19疫苗的新型蛋白质和核酸序列 Download PDF

Info

Publication number
CN117915945A
CN117915945A CN202280048066.0A CN202280048066A CN117915945A CN 117915945 A CN117915945 A CN 117915945A CN 202280048066 A CN202280048066 A CN 202280048066A CN 117915945 A CN117915945 A CN 117915945A
Authority
CN
China
Prior art keywords
leu
ser
thr
val
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280048066.0A
Other languages
English (en)
Chinese (zh)
Inventor
M·阿莱格雷蒂
A·西米尼
A·R·贝卡利
C·塔拉里科
E·M·E·毛里
F·卡塔尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe Farmaceutici SpA
Original Assignee
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farmaceutici SpA filed Critical Dompe Farmaceutici SpA
Publication of CN117915945A publication Critical patent/CN117915945A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280048066.0A 2021-05-14 2022-05-16 用于covid-19疫苗的新型蛋白质和核酸序列 Pending CN117915945A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21173941.2A EP4088738A1 (en) 2021-05-14 2021-05-14 Novel protein and nucleic acid sequences for covid-19 vaccines
EP21173941.2 2021-05-14
PCT/EP2022/063214 WO2022238585A1 (en) 2021-05-14 2022-05-16 Novel protein and nucleic acid sequences for covid-19 vaccines

Publications (1)

Publication Number Publication Date
CN117915945A true CN117915945A (zh) 2024-04-19

Family

ID=75936784

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280048066.0A Pending CN117915945A (zh) 2021-05-14 2022-05-16 用于covid-19疫苗的新型蛋白质和核酸序列

Country Status (10)

Country Link
US (1) US20250282831A1 (cg-RX-API-DMAC7.html)
EP (2) EP4088738A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024517345A (cg-RX-API-DMAC7.html)
CN (1) CN117915945A (cg-RX-API-DMAC7.html)
AU (1) AU2022272659A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023023794A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219586A1 (cg-RX-API-DMAC7.html)
IL (1) IL308407A (cg-RX-API-DMAC7.html)
WO (1) WO2022238585A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202311432B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024245344A1 (zh) * 2023-05-30 2024-12-05 石药集团巨石生物制药有限公司 预防新型冠状病毒奥密克戎突变株的mRNA疫苗

Also Published As

Publication number Publication date
EP4088738A1 (en) 2022-11-16
CA3219586A1 (en) 2022-11-17
AU2022272659A1 (en) 2023-11-23
JP2024517345A (ja) 2024-04-19
WO2022238585A1 (en) 2022-11-17
AU2022272659A9 (en) 2023-11-30
ZA202311432B (en) 2025-04-30
US20250282831A1 (en) 2025-09-11
IL308407A (en) 2024-01-01
BR112023023794A2 (pt) 2024-03-12
EP4337250A1 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
Kremmer et al. Separation of PP2A core enzyme and holoenzyme with monoclonal antibodies against the regulatory A subunit: abundant expression of both forms in cells
Segarini et al. The low density lipoprotein receptor-related protein/α2-macroglobulin receptor is a receptor for connective tissue growth factor
JP3595552B2 (ja) ヘレグリンの構造、生産および用途
Ord et al. A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein
KR102569204B1 (ko) B형 간염 바이러스 감염에 대한 치료 백신접종을 위한 합성 롱 펩티드(slp)
JP5042237B2 (ja) 血小板抗原特異抗体の結合を中和するペプチドアプタマー並びにそれを含む診断及び治療への応用
EP2970397A2 (en) Polypeptides for treating and/or limiting influenza infection
Marangoni et al. Unmasking Snake Venom of Bothrops leucurus: Purification and Pharmacological and Structural Characterization of New PLA2 Bleu TX‐III
Strydom et al. An Angiogenic Protein from Bovine Serum and Milk—Purification and Primary Structure of Angiogenin‐2
WO2002092626A2 (en) Cleavage and polyadenylation complex of precursor mrna
US20250282831A1 (en) Novel protein and nucleic acid sequences for covid-19 vaccines
Maresh et al. Differential processing and secretion of the melanoma-associated ME20 antigen
US20240180889A1 (en) Combination therapy for covid-19 vaccination
US20120071399A1 (en) Sulfation of wnt pathway proteins
KR101123130B1 (ko) Ｐｔｋ７ 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제
CN109897106B (zh) 纳米抗体及其制备方法和应用
WO2016033168A1 (en) Polypeptides and their use for treating influenza
Hattori et al. Generation of monoclonal antibodies against mitocryptide‐2: toward a new strategy to investigate the biological roles of cryptides
WO2010118404A2 (en) Methods for creating or identifying compounds that bind tumor necrosis factor alpha
WO2022105922A1 (zh) 源自于ssx2抗原的短肽
Pike et al. Simple, automated, high resolution mass spectrometry method to determine the disulfide bond and glycosylation patterns of a complex protein: subgroup A avian sarcoma and leukosis virus envelope glycoprotein
CN112300261B (zh) 一种衍生自afp的肿瘤抗原短肽
EP2207799A2 (en) Use of n-terminal and c-terminal proteomics technology to enhance protein therapeutics and diagnostics
HK40069662B (en) Monoclonal antibody against novel coronavirus s protein and use thereof
WO1999038971A1 (fr) Proteine se liant a la midkine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination